Abiraterone, or abiraterone acetate tablets, are usually not available for patients with bone metastases to determine exactly how long they will live, and most patients have a five-year survival rate of 60% or more, meaning that 60% of patients survive for five years or more. The five-year survival rate is commonly used in medicine to indicate the probability of survival after a patient has undergone treatment. Abiraterone acetate tablets are hormonal drugs that are commonly used in clinical practice to treat patients with advanced prostate cancer who have bone metastases. In the early stage of bone metastasis, there is no bone pain, so it is often ignored, but with the development of the disease, there will be obvious bone pain symptoms in the later stage, and local radioactive aggregation will appear in the whole body bone scan, suggesting a bone metastasis lesion. Since most prostate cancers are hormone-dependent, they are mainly treated with hormones in clinical practice. Although the cancer cells in the early stage will show obvious apoptosis, the advanced stage will often show obvious hormone resistance symptoms, such as PSA (prostate-specific antigen) significantly increased or PSA no longer decreased. At this time, patients need to follow medical advice to take oral abiraterone acetate tablets for treatment to control the effects of hormones on the organism, which helps to prolong the survival of patients. However, it is worth noting that the five-year survival rate of patients with prostate cancer bone metastases taking abiraterone acetate tablets is above 60%, which is only a statistical data and does not represent the personal situation of patients. It is recommended that patients actively cooperate with treatment, such as choosing chemotherapy, radiotherapy and surgery, all of which can help patients prolong their survival to a certain extent.